A new paradigm tumor for drug development

被引：21

作者：

Eggermont, Alexander M. M. ^{[1
]}

Robert, Caroline ^{[1
]}

机构：

[1] Inst Cancerol Gustave Roussy, F-94805 Paris, France

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2012年 / 9卷 / 02期

关键词：

BRAF;

D O I：

10.1038/nrclinonc.2011.201

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Melanoma has emerged as the paradigm tumor for drug development through mutation-targeted therapies (inhibitors targeting BRAF, MEK, and c-KIT) and immunotherapy. Exploring the combinations of both approaches is a challenge that will require scientific rationale and the cooperation of the pharmaceutical industry. But, with these challenges comes another opportunity to change the paradigms in drug development. Eggermont, A. M. M. & Robert, C. Nat. Rev. Clin. Oncol. 9, 74-76 (2012); published online 10 January 2012; doi:10.1038/nrclinonc.2011.201

引用

页码：74 / 76

页数：3

共 10 条

[1]

Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].

Brahmer, Julie R. ;

Drake, Charles G. ;

Wollner, Ira ;

Powderly, John D. ;

Picus, Joel ;

Sharfman, William H. ;

Stankevich, Elizabeth ;

Pons, Alice ;

Salay, Theresa M. ;

McMiller, Tracee L. ;

Gilson, Marta M. ;

Wang, Changyu ;

Selby, Mark ;

Taube, Janis M. ;

Anders, Robert ;

Chen, Lieping ;

Korman, Alan J. ;

Pardoll, Drew M. ;

Lowy, Israel ;

Topalian, Suzanne L. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175

[2]

KIT as a Therapeutic Target in Metastatic Melanoma [J].

Carvajal, Richard D. ;

Antonescu, Cristina R. ;

Wolchok, Jedd D. ;

Chapman, Paul B. ;

Roman, Ruth-Ann ;

Teitcher, Jerrold ;

Panageas, Katherine S. ;

Busam, Klaus J. ;

Chmielowski, Bartosz ;

Lutzky, Jose ;

Pavlick, Anna C. ;

Fusco, Anne ;

Cane, Lauren ;

Takebe, Naoko ;

Vemula, Swapna ;

Bouvier, Nancy ;

Bastian, Boris C. ;

Schwartz, Gary K. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (22) :2327-2334

[3]

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation [J].

Chapman, Paul B. ;

Hauschild, Axel ;

Robert, Caroline ;

Haanen, John B. ;

Ascierto, Paolo ;

Larkin, James ;

Dummer, Reinhard ;

Garbe, Claus ;

Testori, Alessandro ;

Maio, Michele ;

Hogg, David ;

Lorigan, Paul ;

Lebbe, Celeste ;

Jouary, Thomas ;

Schadendorf, Dirk ;

Ribas, Antoni ;

O'Day, Steven J. ;

Sosman, Jeffrey A. ;

Kirkwood, John M. ;

Eggermont, Alexander M. M. ;

Dreno, Brigitte ;

Nolop, Keith ;

Li, Jiang ;

Nelson, Betty ;

Hou, Jeannie ;

Lee, Richard J. ;

Flaherty, Keith T. ;

McArthur, Grant A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) :2507-2516

[4]

Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991 [J].

Eggermont, Alexander M. M. ;

Suciu, Stefan ;

Testori, Alessandro ;

Kruit, Wim H. ;

Marsden, Jeremy ;

Punt, Cornelis J. ;

Santinami, Mario ;

Sales, Francois ;

Schadendorf, Dirk ;

Patel, Poulam ;

Dummer, Reinhard ;

Robert, Caroline ;

Keilholz, Ulrich ;

Yver, Antoine ;

Spatz, Alan .

EUROPEAN JOURNAL OF CANCER, 2012, 48 (02) :218-225

[5]

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma [J].

Flaherty, Keith T. ;

Puzanov, Igor ;

Kim, Kevin B. ;

Ribas, Antoni ;

McArthur, Grant A. ;

Sosman, Jeffrey A. ;

O'Dwyer, Peter J. ;

Lee, Richard J. ;

Grippo, Joseph F. ;

Nolop, Keith ;

Chapman, Paul B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (09) :809-819

[6]

Immunogenic and tolerogenic cell death [J].

Green, Douglas R. ;

Ferguson, Thomas ;

Zitvogel, Laurence ;

Kroemer, Guido .

NATURE REVIEWS IMMUNOLOGY, 2009, 9 (05) :353-363

[7]

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma [J].

Hodi, F. Stephen ;

O'Day, Steven J. ;

McDermott, David F. ;

Weber, Robert W. ;

Sosman, Jeffrey A. ;

Haanen, John B. ;

Gonzalez, Rene ;

Robert, Caroline ;

Schadendorf, Dirk ;

Hassel, Jessica C. ;

Akerley, Wallace ;

van den Eertwegh, Alfons J. M. ;

Lutzky, Jose ;

Lorigan, Paul ;

Vaubel, Julia M. ;

Linette, Gerald P. ;

Hogg, David ;

Ottensmeier, Christian H. ;

Lebbe, Celeste ;

Peschel, Christian ;

Quirt, Ian ;

Clark, Joseph I. ;

Wolchok, Jedd D. ;

Weber, Jeffrey S. ;

Tian, Jason ;

Yellin, Michael J. ;

Nichol, Geoffrey M. ;

Hoos, Axel ;

Urba, Walter J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (08) :711-723

[8]

Improved Endpoints for Cancer Immunotherapy Trials [J].

Hoos, Axel ;

Eggermont, Alexander M. M. ;

Janetzki, Sylvia ;

Hodi, F. Stephen ;

Ibrahim, Ramy ;

Anderson, Aparna ;

Humphrey, Rachel ;

Blumenstein, Brent ;

Old, Lloyd ;

Wolchok, Jedd .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (18) :1388-1397

[9]

Infante JR, 2011, J CLIN ONCOL, V29

[10]

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma [J].

Robert, Caroline ;

Thomas, Luc ;

Bondarenko, Igor ;

O'Day, Steven ;

Weber, Jeffrey ;

Garbe, Claus ;

Lebbe, Celeste ;

Baurain, Jean-Francois ;

Testori, Alessandro ;

Grob, Jean-Jacques ;

Davidson, Neville ;

Richards, Jon ;

Maio, Michele ;

Hauschild, Axel ;

Miller, Wilson H., Jr. ;

Gascon, Pere ;

Lotem, Michal ;

Harmankaya, Kaan ;

Ibrahim, Ramy ;

Francis, Stephen ;

Chen, Tai-Tsang ;

Humphrey, Rachel ;

Hoos, Axel ;

Wolchok, Jedd D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) :2517-2526

← 1 →